AI Summary
Evotec issued preliminary Q2 and H1 results with €300.1m revenue and -€42.7m adjusted EBITDA, alongside a widened liquidity cushion of about €465.6m. The full-year revenue outlook was cut to €570–€610m and EBITDA to -€70 to -€105m, a sharp downgrade from prior guidance of €700–€780m and €0–€40m, signaling higher cash burn and balance-sheet risk ahead of Aug 13 results.
Sentiment Rationale
The company slashed full-year guidance dramatically from €700-€780m revenue and €0-€40m EBITDA to €570-€610m and -€70 to -€105m, signaling higher cash burn and earnings stress. Historically, such downgrades trigger immediate stock weakness, especially when paired with a weak H1 EBITDA print and a still-elevated burn rate; the Aug 13 results become the near-term price catalyst.
Trading Thesis
Near-term downside risk persists until Aug 13 results clarify profitability trajectory and liquidity needs.
Market-Moving
- Guidance downgrade likely pressures EVO shares ahead of Aug 13 results.
- H1 liquidity cushion of €465.6m buys time but worsens cash burn outlook.
- Next catalyst: August 13, 2026 full results release.
- Negative EBITDA outlook widens investor concerns on profitability.
Key Facts
- Evotec reports H1 2026 revenue €300.1m; liquidity €465.6m.
- Full-year 2026 guidance lowered to €570–€610m revenue; EBITDA -€70 to -€105m.
- Prior guidance was €700–€780m revenue; €0–€40m EBITDA.
- Results release scheduled for Aug 13, 2026.
Companies Mentioned
- Evotec SE (EVO): US-listed; 2026 outlook cut amid weaker H1; negative earnings trajectory.
- Evotec SE (EVT): Frankfurt listing; downgrade risk reflected in European market.
Earnings
Category: Earnings. Evotec's release provides preliminary Q2/H1 results and updated 2026 outlook, a clear earnings-driven update affecting valuation and liquidity considerations.